Browsing publications by Dr Julie Irving

Newcastle AuthorsTitleYearFull text
Professor Anthony Moorman
Dr Julie Irving
Professor James Allan
Professor Christine Harrison
A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.12017
Dr Britta Vormoor
Dr Gareth Veal
Melanie Griffin
Dr Julie Irving
Lynne Minto
et al.
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia2017
Zach Dixon
Dr Lindsay Nicholson
Elizabeth Matheson
Dr Paul Sinclair
Professor Christine Harrison
et al.
CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response2017
Dr Julie Irving
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia2017
Dr Julie Irving
Acute lymphoblastic leukemia in the context of RASopathies2016
Judith Weiland
Dr Deepali Pal
Marian Case
Dr Julie Irving
Dr Frida Ponthan
et al.
BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance2016
Dr Julie Irving
Dr Amir Enshaei
Dr Amy Erhorn
Lynne Minto
Claire Schwab
et al.
Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukaemia2016
Rosanna Jackson
Dr Julie Irving
Dr Gareth Veal
Personalisation of dexamethasone therapy in childhood acute lymphoblastic leukaemia2016
Dr Alex Elder
Dr Klaus Rehe
Dr Simon Bomken
Dr Paul Sinclair
Katie Dormon
et al.
The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts.2016
Dr Julie Irving
The Biology, Prognostic Relevance, and Targeted Treatment of Ras Pathway-Positive Childhood Acute Lymphoblastic Leukemia2016
123456789101112